CHARLES M. BAUM - 29 Dec 2023 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
Interim CEO, Director
Signature
/s/ John Moriarty, Attorney-in-Fact
Issuer symbol
MRTX
Transactions as of
29 Dec 2023
Net transactions value
+$1,199,969
Form type
4
Filing time
03 Jan 2024, 17:52:40 UTC
Previous filing
10 Aug 2023
Next filing
23 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $1,199,969 +20,425 +9% $58.75 247,700 29 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 (1) Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.